The industrial-grade portable sanitation company is rapidly scaling its presence across the United States, with active service now live in California, Illinois, New York, and Tennessee — and a full
ZettaMine AI Lab at Hyderabad Pioneering AI Model Training with Expert Raters, AI Co-Pilots & Synthetic Data for Frontier AI companies Hyderabad, India – 5 June 2026 – PlatinaData AI,
The Key Gastroparesis Companies CinDome Pharma, Inc., Evoke Pharma, Vanda Pharmaceuticals, Ironwood Pharmaceuticals, Takeda, Neurogastrx, Inc, PTC Therapeutics, Theravance Biopharma, Chugai Pharma, GlaxoSmithKline, Processa Pharmaceuticals, and others. DelveInsight’s “Gastroparesis
The Key Focal Segmental Glomerulosclerosis Companies in the market include – Evergreen Therapeutics, Certa Therapeutics, River 3 Renal Corp, Boehringer Ingelheim, Dimerix Bioscience, Travere Therapeutics, Dimerix, Goldfinch Bio, Vertex Pharmaceuticals,
The Key Anal Cancer Companies in the market include – Incyte Corporation, BioMimetix, Inovio Pharmaceuticals, Merck Sharp & Dohme, Dustin Deming, Advaxis, Inc., Oryx GmbH & Co. KG, and others.
The Key Cytokine Release Syndrome Companies in the market include – Genentech, Swedish Orphan Biovitrum (sobi), Incyte, Kite, A Gilead Company, Jazz Pharmaceuticals, Fred Hutchinson Cancer Center, Ontario Clinical Oncology
Key companies like Astellas Pharma/Iveric Bio, Apellis Pharmaceuticals, Belite Bio, Alkeus Pharmaceuticals, Aviceda Therapeutics, Allegro Ophthalmics, Johnson & Johnson Innovative Medicine, and others are leading the exponential growth in the
DelveInsight’s “Fuchs Endothelial Corneal Dystrophy Market Insights, Epidemiology, and Market Forecast-2036” report offers an in-depth understanding of Fuchs Endothelial Corneal Dystrophy, historical and forecasted epidemiology as well as the FECD
DelveInsight’s “Chronic Obstructive Pulmonary Disease Pipeline Insight 2026” report provides comprehensive insights about 65+ companies and 75+ pipeline drugs in the Chronic Obstructive Pulmonary Disease pipeline landscape. It covers the
DelveInsight’s “CAR T-Cell Therapy Pipeline Insight 2026” report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in the CAR T-Cell Therapy pipeline landscape. It covers the CAR T-Cell
